APA (7th ed.) Citation

Pöschel, V., Held, G. W., Ziepert, M., Witzens-Harig, M., Holte, H., Thurner, L., . . . Pfreundschuh, M. (2019). Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): A randomised, phase 3, non-inferiority trial. The lancet, 394(10216), . https://doi.org/10.1016/S0140-6736(19)33008-9

Chicago Style (17th ed.) Citation

Pöschel, Viola, et al. "Four Versus Six Cycles of CHOP Chemotherapy in Combination with Six Applications of Rituximab in Patients with Aggressive B-cell Lymphoma with Favourable Prognosis (FLYER): A Randomised, Phase 3, Non-inferiority Trial." The Lancet 394, no. 10216 (2019). https://doi.org/10.1016/S0140-6736(19)33008-9.

MLA (9th ed.) Citation

Pöschel, Viola, et al. "Four Versus Six Cycles of CHOP Chemotherapy in Combination with Six Applications of Rituximab in Patients with Aggressive B-cell Lymphoma with Favourable Prognosis (FLYER): A Randomised, Phase 3, Non-inferiority Trial." The Lancet, vol. 394, no. 10216, 2019, https://doi.org/10.1016/S0140-6736(19)33008-9.